This phenomenon-whereby cytotoxic payloads released from dying tumor cells exert cytotoxic effects on adjacent cells-proves particularly valuable for eliminating HER2-low cells and addressing tumoral heterogeneity (Li et al., 2016). The gene discussed is ERBB2; the disease is neoplasm.